Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Hello, everyone, and I hope you are doing well today. After surviving the middle of the week, we are determined to make the most of the remaining days. To keep ourselves occupied, we have a delightful flavor for you today: butter pecan. We trust you are having a wonderful day and please do stay in touch.

Recently, a group of physicians and Prader-Willi syndrome experts have alerted healthcare professionals about a series of patient deaths and severe side effects potentially linked to Vykat XR, a recently approved drug by Neurocrine Biosciences. According to the FDA's Adverse Event Monitoring System, seven individuals prescribed Vykat have tragically passed away, while over 100 reports of serious adverse events have been filed, primarily involving hospitalizations for swelling, respiratory, and heart complications.

Eli Lilly has taken a strong stance against the unauthorized sale of its experimental obesity drug, retatrutide, by filing six lawsuits against U.S. companies. These businesses, including compounding pharmacies, medical spas, and online sellers, allegedly marketed retatrutide to consumers even though the drug is still in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. Retatrutide remains under regulatory approval.